Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
作者： Chalirmporn Atasilp , Phichai Chansriwong , Ekaphop Sirachainan , Thanyanan Reungwetwattana , Suwannee Sirilerttrakul
DOI: 10.1038/S41598-020-70351-0
关键词:
摘要: Genetic polymorphisms in drug metabolizing enzymes and transporters may affect irinotecan toxicity. Although genetic have been shown to influence the toxicity, data are limited Thai population. Thus, aim of this study was assess allele genotype frequencies relationship between CYP3A4/5, DPYD, UGT1A1, ABCB1, ABCC2 variations irinotecan-induced toxicity colorectal cancer patients. One hundred thirty-two patients were genotyped, effect on assessed 66 who received irinotecan-based chemotherapy. Allele ABCB1 c.1236C > T, c.3435C > T, c.3972C > T, ABCG2 c.421C > A, CYP3A4*1B, CYP3A4*18, CYP3A5*3, DPYD*5, UGT1A1*28, UGT1A1*6 0.67, 0.43, 0.23, 0.27, 0.01, 0.02, 0.64, 0.19, 0.16, 0.09, respectively. DPYD*2A DPYD c.1774C > T variants not detected our The c.3972C > T significantly associated with grade 1–4 neutropenia (P T might be an important predictor for severe neutropenia.
nature.com
scilit.net参考文章(41)
G Gentile, A Botticelli, L Lionetto, F Mazzuca, M Simmaco, P Marchetti, M Borro, Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction. Pharmacogenomics Journal. ,vol. 16, pp. 320- 325 ,(2016) , 10.1038/TPJ.2015.56
Chonlaphat Sukasem, Chalirmporn Atasilp, Pichai Chansriwong, Montri Chamnanphon, Apichaya Puangpetch, Ekapob Sirachainan, Development of Pyrosequencing Method for Detection of UGT1A1 Polymorphisms in Thai Colorectal Cancers. Journal of Clinical Laboratory Analysis. ,vol. 30, pp. 84- 89 ,(2016) , 10.1002/JCLA.21820
Chung-Pin Li, Sang-Hue Yen, Jiing-Chyuan Luo, Ying-Ying Wu, Chien-Hui Kao, Yee Chao, Sung-Hao Huang, Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer. Tumori. ,vol. 97, pp. 243- 247 ,(2011) , 10.1700/667.7793
Jun Zhang, Chen Yang, Ying Liu, Wenqi Xi, Chenfei Zhou, Jinling Jiang, Tao Ma, Zhengbao Ye, Zhenggang Zhu, Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. Drug Design Development and Therapy. ,vol. 9, pp. 3677- 3683 ,(2015) , 10.2147/DDDT.S86750
Chen-fei Zhou, Tao Ma, Yang Su, Zheng-bao Ye, Jun Ji, Ying-yan Yu, Jun Zhang, Bing-ya Liu, Zheng-gang Zhu, UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. Anti-cancer Agents in Medicinal Chemistry. ,vol. 13, pp. 235- 241 ,(2013) , 10.2174/1871520611313020008
Yuichi Ando, Yoshinori Hasegawa, Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metabolism Reviews. ,vol. 37, pp. 565- 574 ,(2005) , 10.1080/03602530500316254
Sompop Bencharit, Christopher L. Morton, Escher L. Howard-Williams, Mary K. Danks, Philip M. Potter, Matthew R. Redinbo, Structural insights into CPT-11 activation by mammalian carboxylesterases. Nature Structural & Molecular Biology. ,vol. 9, pp. 337- 342 ,(2002) , 10.1038/NSB790
Thierry Cresteil, Bernard Monsarrat, Joelle Dubois, Michelle Sonnier, Paul Alvinerie, Françoise Gueritte, Regioselective Metabolism of Taxoids by Human CYP3A4 and 2C8: Structure-Activity Relationship Drug Metabolism and Disposition. ,vol. 30, pp. 438- 445 ,(2002) , 10.1124/DMD.30.4.438
Masashi Takano, Masafumi Kato, Tomoyuki Yoshikawa, Naoki Sasaki, Junko Hirata, Kenichi Furuya, Michiko Takahashi, Harushige Yokota, Nao Kino, Koji Horie, Tomoko Goto, Keiichi Fujiwara, Kenji Ishii, Yoshihiro Kikuchi, Tsunekazu Kita, Clinical Significance of UDP-Glucuronosyltransferase 1A1*6 for Toxicities of Combination Chemotherapy with Irinotecan and Cisplatin in Gynecologic Cancers Oncology. ,vol. 76, pp. 315- 321 ,(2009) , 10.1159/000209335
Hiroshi Suzuki, Yuichi Sugiyama, Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition Advanced Drug Delivery Reviews. ,vol. 54, pp. 1311- 1331 ,(2002) , 10.1016/S0169-409X(02)00075-3